Moving toward the next steps in angiogenesis therapy?

Neuro-Oncology

Volumn 10, Issue 6, 2008, Pages 939-

  Yung, W K Alfred ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; VASCULOTROPIN A;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER GROWTH; CANCER REGRESSION; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; EXPERIMENTAL MODEL; GLIOBLASTOMA; GLIOMA; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; NOTE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60549112401     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-091     Document Type: Editorial

References (6)

1. Weller M. and Yung W.K.A. Bevacizumab-News from the Fast Lane? Neuro-Oncology 2008;10:647.
2. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology, 2008;10:940.
3. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. [serial online] October 3, 2008. Available at http://thejns.org/doi/pdf/10.3171/2008.4.17492.
4. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787.
5. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
6. de Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 [abstr. #2020]. J Clin Oncol. 2008;26(suppl).